Synthetic Biology Cross-Border Ip Arbitration Strategies.
I. Overview: Synthetic Biology and Cross-Border IP Disputes
1. Synthetic Biology
Synthetic biology involves designing and constructing new biological entities or modifying existing ones using engineering principles. Key IP assets include:
Patents on engineered organisms, genetic circuits, and synthetic pathways
Trade secrets for proprietary processes and biological materials
Copyright or software protection for bioinformatics algorithms
2. Cross-Border IP Issues
When synthetic biology companies operate internationally, disputes often arise regarding:
Patent ownership and enforcement in multiple jurisdictions
Licensing rights across borders
Biopiracy and access to genetic resources
Regulatory divergence between countries (e.g., US, EU, India, China)
Arbitration is often chosen because of:
Confidentiality in sensitive biotech disputes
Expertise of arbitrators in IP law
Enforcement advantages under the New York Convention
II. Key Cross-Border IP Arbitration Strategies
Choice of Law and Forum
Decide which jurisdiction’s IP law governs the dispute
Use arbitration clauses specifying arbitration venue and rules (ICC, LCIA, SIAC)
Patent Scope and Validity Assessment
Review differences in patentability standards (e.g., isolated genes, engineered organisms)
Evaluate potential oppositions and revocations
Confidentiality Protection
Use non-disclosure agreements and protective measures for proprietary sequences and synthetic constructs
Risk Allocation in Licensing Agreements
Specify territorial IP rights and sublicensing restrictions
Address royalties, infringement liability, and regulatory approvals
Technical Expert Involvement
Engage experts in molecular biology, synthetic biology, and bioinformatics to support arbitration
Enforcement Considerations
Ensure arbitration awards are enforceable internationally under conventions like the New York Convention
III. Case Laws Relevant to Cross-Border IP Arbitration in Synthetic Biology
Case 1: Association for Molecular Pathology v. Myriad Genetics (2013)
Facts
Myriad patented isolated human genes (BRCA1/2).
Challenge arose regarding whether naturally occurring genes are patentable.
Relevance
In cross-border arbitration, Myriad’s patents were vulnerable due to differing jurisdictional standards.
Strategy: Assess patent enforceability in target countries before initiating arbitration.
Case 2: Diamond v. Chakrabarty (1980)
Facts
Genetically engineered microorganism was patented in the US.
Relevance
Establishes that engineered biological entities are patentable in the US.
Cross-border arbitration strategy: Ensure patent claims are engineered and novel, not mere discoveries, for enforceability internationally.
Case 3: Monsanto Technology LLC v. Cefetra BV (2010)
Facts
Patent disputes over herbicide-resistant GM seeds.
Relevance
Cross-border enforcement issues arose when seeds moved through multiple jurisdictions.
Arbitration strategies include:
Contractual definition of territorial rights
Clear licensing clauses for cross-border use
Identification of potential infringement risk areas
Case 4: Harvard College v. Canada (OncoMouse Case, 2002)
Facts
Harvard’s patent on genetically modified mice was partially denied in Canada (higher life forms not patentable).
Relevance
Demonstrates jurisdictional divergence in patent eligibility.
Arbitration strategy: Pre-assess local patent law before disputes arise; use choice-of-law clauses.
Case 5: CRISPR-Cas9 Patent Interference (Broad Institute vs. UC Berkeley)
Facts
Global disputes over inventorship and priority in CRISPR patents.
Arbitration Implications
Cross-border disputes may require neutral arbitration to resolve inventorship, licensing, and royalty allocations.
Strategy:
Detailed IP ownership records
Binding arbitration clauses for international licensing
Case 6: Novartis AG v. Union of India (2013)
Facts
India rejected a patent for a modified drug due to lack of enhanced efficacy.
Relevance
Cross-border IP enforcement may be affected by local patentability standards and public interest exceptions.
Strategy: Anticipate revocation risks in arbitration; adjust licensing or royalty agreements accordingly.
Case 7: Roche Molecular Systems, Inc. v. Cepheid (2008)
Facts
Dispute over broad claims in PCR and DNA detection patents.
Arbitration Relevance
Arbitration can handle technical disputes about claim scope confidentially.
Strategy:
Use scientific expert testimony in arbitration
Narrow patent claims to strengthen enforceability
Consider mediation before escalation
IV. Practical Cross-Border Arbitration Strategies
Draft Strong Arbitration Clauses
Specify venue, governing law, procedural rules, and language.
Conduct Pre-Arbitration IP Audit
Validate patents, check for oppositions, revocations, or interferences.
Use Confidential Expert Panels
Biotech and AI experts can clarify complex technical issues for arbitrators.
Plan for Multijurisdictional Enforcement
Anticipate differences in patent validity and enforce arbitration awards internationally.
Include Ethical and Regulatory Compliance
Address biosafety, public order, and ethical considerations in the arbitration agreement.
Mitigate Risk Through Licensing
Define clear sublicensing, royalties, and cross-border IP use rights.
V. Key Takeaways
Synthetic biology IP is highly jurisdiction-sensitive, with different countries recognizing patents differently.
Cross-border arbitration is essential for confidential, technical, and enforceable dispute resolution.
Case law demonstrates the need to validate patent scope, novelty, and enforceability before disputes.
Effective arbitration strategies include:
Choice of law clauses
Expert technical input
Confidentiality measures
Clear licensing and risk allocation
RELATED Blog
comments